Krele is developing high impact prescription drugs for unmet medical needs.  Krele has targeted intractable problems with fresh ideas and experienced scientists and drug developers.

Krele’s Mission

Our products will make a difference. Our clinical development programs are tailored to the specific challenges of targeted conditions.

Krele’s Business

Krele has a portfolio of drug product candidates. Krele tailors development to meet the challenges of each condition. Krele seeks to maintain options for commercialization as a stand-alone entity while maximizing strategic business development options such as co-marketing partnerships.

Product development at Krele combines efficient clinical development with market insight. Our resulting drug products are designed to provide compelling value proposals to patients and prescribers, as well as demonstrate clear competitive advantages to third-party payors (such as insurance companies or government programs like Medicare) to merit reimbursement.

Krele is a subsidiary of TONIX Pharmaceuticals (www.tonixpharma.com).

Krele’s strategic principles include:

1) Focus on U.S. market – The U.S. is the largest pharmaceutical market in the world. The U.S. is also attractive because partners and collaborators recognize the value of differentiated products in this market.

2) Maintain option of stand-alone marketing – Specialist physicians are grouped into several niche markets such as: psychiatrists, neurologists or addiction medicine doctors. A niche market can be targeted through a small specialty sales force, allowing Krele to retain the value created in the developed product.